Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Nasdaq Real Time Price USD

Allurion Technologies Inc. (ALUR)

Compare

2.7800

-0.1200

(-4.14%)

At close: April 7 at 4:00:02 PM EDT

2.7001

-0.08

(-2.87%)

After hours: April 7 at 7:55:56 PM EDT

Allurion Announces Postponement of Special Meeting of Stockholders

NATICK, Mass., April 03, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM

Business Wire 4 days ago

ALUR
-4.14%
ALUR-WS
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

NATICK, Mass., March 26, 2025--Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

Business Wire 12 days ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass., March 20, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.

Business Wire 18 days ago

ALUR
-4.14%
ALUR-WS
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

NATICK, Mass., March 12, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Business Wire 26 days ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass., March 04, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled "Automatic-Sealing Balloon-Filling Catheter System" and U.S. Patent No. 12,245,962 titled "Balloon Sealing and Fill Valve". These patents, both of which are scheduled to issue on March

Business Wire last month

ALUR
-4.14%
ALUR-WS
Allurion to Participate in Upcoming Investor Conferences

NATICK, Mass., February 25, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.

Business Wire last month

ALUR
-4.14%
ALUR-WS
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass., February 20, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price

Business Wire last month

ALUR
-4.14%
ALUR-WS
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass., February 19, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share in a registered direct offering. In addition, the Company will issue to the investors warrants to purchase up to 1,800,000 shares

Business Wire last month

ALUR
-4.14%
ALUR-WS
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

NATICK, Mass., February 18, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy.

Business Wire last month

ALUR
-4.14%
ALUR-WS
Allurion Relaunches in France

NATICK, Mass., February 13, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales.

Business Wire last month

ALUR
-4.14%
ALUR-WS
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

ALUR
-4.14%
ALUR-WS
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investor's Business Daily 2 months ago

NONOF

NVO

ALUR
-4.14%
Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement

The stock rally followed news of a planned study combining the Allurion Program with GLP-1 therapies.

GuruFocus.com 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

NATICK, Mass., January 24, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules.

Business Wire 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

NATICK, Mass., January 23, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Business Wire 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass., January 21, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled "Binary Fluid Control Valve System". This patent covers additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology and the introduction of in

Business Wire 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass., January 14, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP ("RTW") for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Compa

Business Wire 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion Announces Positive Topline Results From AUDACITY Trial

NATICK, Mass., January 08, 2025--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon.

Business Wire 2 months ago

ALUR
-4.14%
ALUR-WS
Allurion Technologies, Inc. Announces Reverse Stock Split

NATICK, Mass., December 24, 2024--Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the "Common Stock").

Business Wire 3 months ago

ALUR
-4.14%
ALUR-WS
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next

The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.

Yahoo Finance 3 months ago

NONOF

NVO

HIMS

Performance Overview

Return	ALUR	S&P 500 (^GSPC)
YTD	-74.14%	-13.93%
1-Year	-95.42%	-2.73%
3-Year	-98.86%	+12.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Allurion Technologies Inc. (ALUR)

Allurion Announces Postponement of Special Meeting of Stockholders

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion to Participate in Upcoming Investor Conferences

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Allurion Relaunches in France

How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion Technologies, Inc. Announces Reverse Stock Split

FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next

Performance Overview